Literature DB >> 6323296

Biosynthesis of abnormally glycosylated alpha 1-antitrypsin by a human hepatoma cell line.

J Carlson, S Eriksson, R Alm, T Kjellström.   

Abstract

The human hepatoma cell line PLC/PRF/5 synthesized and secreted a functional alpha 1-antitrypsin (alpha 1-AT) glycoprotein with normal molecular size but retarded electrophoretic mobility. The total process of translation, glycosylation and export required about 40 min and followed the same synthetic pattern as seen in rat hepatocytes, i.e., a signal peptide is cleaved cotranslationally; a core-glycosylated protein in the high-mannose form is formed in the rough endoplasmic reticulum, trimmed, and a stable complex-glycosylated alpha 1-AT is found intracellularly prior to export. alpha 1-AT export to medium was delayed by tunicamycin, inhibited by cycloheximide but unaffected by colchicine. After addition of exogenous alpha 1-AT to culture medium, neither negative nor positive feedback induction of synthesis could be demonstrated. Electrophoretic techniques indicated the presence of atypical, highly branched but incompletely sialylated carbohydrate chains in the hepatoma cell-derived alpha 1-AT. The accumulation of intracellular alpha 1-AT inclusions seen in the endoplasmic reticulum may reflect an imbalance between a high rate of polypeptide synthesis and terminal glycosylation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323296     DOI: 10.1002/hep.1840040211

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines.

Authors:  A Mackiewicz; D Schultz; J Mathison; M Ganapathi; I Kushner
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages.

Authors:  D H Perlmutter; F S Cole; P Kilbridge; T H Rossing; H R Colten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

3.  Oncostatin M and TNF-α Induce Alpha-1 Antitrypsin Production in Undifferentiated Adipose Stromal Cells.

Authors:  Kevin Ni; Muhammad Umair Mukhtar Mian; Catherine Meador; Amar Gill; Daria Barwinska; Danting Cao; Matthew J Justice; Di Jiang; Niccolette Schaefer; Kelly S Schweitzer; Hong Wei Chu; Keith L March; Irina Petrache
Journal:  Stem Cells Dev       Date:  2017-09-21       Impact factor: 3.272

Review 4.  Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms.

Authors:  G A Turner; M T Goodarzi; S Thompson
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

5.  Modeling and integration of N-glycan biomarkers in a comprehensive biomarker data model.

Authors:  Daniel F Lyman; Amanda Bell; Alyson Black; Hayley Dingerdissen; Edmund Cauley; Nikhita Gogate; David Liu; Ashia Joseph; Robel Kahsay; Daniel J Crichton; Anand Mehta; Raja Mazumder
Journal:  Glycobiology       Date:  2022-09-19       Impact factor: 5.954

6.  Changes of immunoreactivity in alpha 1-antitrypsin in patients with autoimmune diseases.

Authors:  L Saso; B Silvestrini; R Lahita; C Y Cheng
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

7.  Long-term biosynthesis of complement component C3 and alpha-1 acid glycoprotein by adult rat hepatocytes in a co-culture system with an epithelial liver cell-type.

Authors:  J P Lebreton; M Daveau; M Hiron; M Fontaine; D Biou; D Gilbert; C Guguen-Guillouzo
Journal:  Biochem J       Date:  1986-04-15       Impact factor: 3.857

8.  Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma.

Authors:  Aleksandra Topic; Mila Ljujic; Dragica Radojkovic
Journal:  Hepat Mon       Date:  2012-10-30       Impact factor: 0.660

9.  Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer.

Authors:  S Thompson; D Guthrie; G A Turner
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.